

**VAV1 Antibody (Center) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP13853c****Specification**

---

**VAV1 Antibody (Center) Blocking peptide - Product Information**

Primary Accession [P15498](#)

**VAV1 Antibody (Center) Blocking peptide - Additional Information**

**Gene ID** 7409

**Other Names**

Proto-oncogene vav, VAV1, VAV

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody AP13853c was selected from the Center region of VAV1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**VAV1 Antibody (Center) Blocking peptide - Protein Information**

**Name** VAV1

**Synonyms** VAV

**Function**

Couples tyrosine kinase signals with the activation of the Rho/Rac GTPases, thus leading to cell differentiation and/or proliferation.

**Tissue Location**

Widely expressed in hematopoietic cells but not in other cell types

**VAV1 Antibody (Center) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

#### **VAV1 Antibody (Center) Blocking peptide - Images**

#### **VAV1 Antibody (Center) Blocking peptide - Background**

The protein encoded by this proto-oncogene is a member of the Dbl family of guanine nucleotide exchange factors (GEF) for the Rho family of GTP binding proteins. The protein is important in hematopoiesis, playing a role in T-cell and B-cell development and activation. This particular GEF has been identified as the specific binding partner of Nef proteins from HIV-1. Coexpression and binding of these partners initiates profound morphological changes, cytoskeletal rearrangements and the JNK/SAPK signaling cascade, leading to increased levels of viral transcription and replication.

#### **VAV1 Antibody (Center) Blocking peptide - References**

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Hollmann, A., et al. Hematol Oncol 28(3):142-150(2010) Barda-Saad, M., et al. EMBO J. 29(14):2315-2328(2010) Davila, S., et al. Genes Immun. 11(3):232-238(2010) Kim, H.S., et al. Immunity 32(2):175-186(2010)